Licensing opportunities

Polyphor offers PEMdrug candidates, which are derived from its proprietary Protein Epitope Mimetic (PEM) Technology platform. The offered products include the following compounds:

  • POL6326 (CXCR4 antagonist, several indications, Phase II)
  • POL7080 (antibiotic, Phase II)
  • POL6014 (elastase inhibitor, pre-clincial)